Repositioning Candidate Details
| Candidate ID: | R0185 |
| Source ID: | DB00649 |
| Source Type: | approved; investigational |
| Compound Type: | small molecule |
| Compound Name: | Stavudine |
| Synonyms: | |
| Molecular Formula: | C10H12N2O4 |
| SMILES: | CC1=CN([C@@H]2O[C@H](CO)C=C2)C(=O)NC1=O |
| Structure: |
|
| DrugBank Description: | A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. |
| CAS Number: | 3056-17-5 |
| Molecular Weight: | 224.2133 |
| DrugBank Indication: | For the treatment of human immunovirus (HIV) infections. |
| DrugBank Pharmacology: | Stavudine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Stavudine is phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit the HIV reverse transcriptase enzyme competitively and act as a chain terminator of DNA synthesis. The lack of a 3'-OH group in the incorporated nucleoside analogue prevents the formation of the 5' to 3' phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth is terminated. |
| DrugBank MoA: | Stavudine inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate dGTP and by its incorporation into viral DNA. |
| Targets: | Reverse transcriptase/RNaseH |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I02 | 1184 | nephrotic syndrome | "A nephrosis characterized by marked increase in glomerular protein permeability resulting in marked elevation of urine protein levels, hypoalbuminemia, hyperlipidemia, and hypercoagulability." [url:https\://en.wikipedia.org/wiki/Nephrotic_syndrome, url:https\://www.niddk.nih.gov/health-information/kidney-disease/nephrotic-syndrome-adults] | Details |